Pantoloc (Pantoprazole)

Pantoprazole, the active ingredient in Pantoloc, is a proton pump inhibitor presented as a tablet for oral use and marketed in the European Union. It reduces gastric acid secretion and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support.

Pantoprazole acts on the gastric proton pump to lower stomach acidity, making it useful for several acid‑related conditions. - Gastro‑oesophageal reflux disease (GERD): relief of heartburn and healing of esophageal irritation. - Erosive oesophagitis: promotes mucosal healing and reduces further damage. - Peptic ulcer disease: supports ulcer healing and prevents recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often resolves without intervention. - Diarrhoea: loose stools that may be self‑limiting. - Nausea: sensation of unease or urge to vomit. - Abdominal pain: discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Clostridioides difficile infection: severe diarrhoea with abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle weakness, irregular heartbeat. - Elevated liver enzymes: possible indication of hepatic stress. - Stevens‑Johnson syndrome: painful skin blistering and mucosal involvement.

Before initiating therapy, certain safety considerations should be observed. - Assess renal function: adjust use in severe renal impairment. - Monitor magnesium levels: especially during prolonged treatment. - Evaluate hepatic status: dose may need modification in liver disease. - Discontinue if hypersensitivity occurs: stop immediately and seek medical advice. - Store at room temperature: keep in the original pack, protect from moisture and light.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole: reduced antifungal absorption. - Atazanavir: decreased antiviral efficacy. - Clopidogrel: diminished antiplatelet activation.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Methotrexate: elevated serum concentrations, watch for toxicity. - Digoxin: potential rise in serum levels, assess cardiac function.